WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, and EXTRAVASATION AND TISSUE NECROSIS
- Cardiomyopathy: IDAMYCIN PFS can cause myocardial damage, including acute left ventricular failure, during or after termination of therapy. The risk of cardiomyopathy is increased in patients who have received prior anthracyclines or who have pre-existing cardiac disease. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment [see Warnings and Precautions (5.1)].
- Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS [see Warnings and Precautions (5.2)].
- Extravasation and Tissue Necrosis: Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately terminate the infusion of IDAMYCIN PFS and institute the recommended management procedures [see Dosage and Administration (2.6) and Warnings and Precautions (5.3)]. WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, and EXTRAVASATION AND TISSUE NECROSIS See full prescribing information for complete boxed warning.
- Cardiomyopathy: Myocardial damage leading to congestive heart failure can occur with IDAMYCIN PFS. Assess left ventricular cardiac function prior to initiation of IDAMYCIN PFS and during and after treatment. (5.1)
- Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including IDAMYCIN PFS. (5.2)
- Extravasation of IDAMYCIN PFS during administration can result in local tissue injury and necrosis. Immediately discontinue the IDAMYCIN PFS infusion if extravasation occurs. (2.6, 5.3)
Use: Labeled indications
- IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1)
Contraindications
4 CONTRAINDICATIONS None. None. (4)
US FDA labelDosing: Adult
- Induction Therapy • 12 mg/m 2 intravenously over 10 to 15 minutes on days 1, 2, and 3 of induction in combination with cytarabine 100 mg/m 2 by continuous intravenous infusion daily for 7 days or cytarabine 25 mg/m 2 intravenous bolus followed by cytarabine 200 mg/m 2 continuous intravenous infusion daily for 5 days. (2.1)
- • IDAMYCIN PFS can be given as part of a combination regimen with other chemotherapeutic drugs. (2.1)
- • Renal Impairment: Assess renal function prior to therapy. Reduce dosage in renal impairment. (2.3, 8.6)
- • Hepatic Impairment: Assess hepatic function prior to therapy. Avoid or reduce dosage in hepatic impairment. (2.4, 8.7)
- See full prescribing information for preparation and administration instructions. (2.5, 2.6)
2.1 Recommended Dosage
2.1 Recommended Dosage Administer IDAMYCIN PFS 12 mg/m 2 intravenously over 10 to 15 minutes on days 1, 2, and 3 of induction in combination with cytarabine. The cytarabine may be given as 100 mg/m 2 by continuous intravenous infusion daily for 7 days or as cytarabine 25 mg/m 2 intravenous bolus followed by cytarabine 200 mg/m 2 continuous intravenous infusion daily for 5 days.
If a response is not achieved with the first induction cycle, a second induction cycle may be administered. Other dosage regimens may be used for a second induction cycle. Individualize the dose and dosing schedule of IDAMYCIN PFS based on the specific regimen administered, disease state, response to treatment, and patient risk factors.
2.2 Dosage Modifications for Adverse Reactions Cardiomyopathy
2.2 Dosage Modifications for Adverse Reactions Cardiomyopathy Discontinue IDAMYCIN PFS in patients who develop signs or symptoms of cardiomyopathy [see Warnings and Precautions (5.1)]. Myelosuppression If patients develop severe myelosuppression, reduce the dose of IDAMYCIN PFS by 25% or as clinically indicated in subsequent cycles [see Warnings and Precautions (5.4)].
Mucositis If patients develop severe mucositis with IDAMYCIN PFS, reduce the dose by 25% in subsequent cycles. If a second cycle is planned, delay administration in patients who develop severe mucositis until this adverse reaction has resolved [see Adverse Reactions (6.1)].
2.3 Recommended
2.3 Recommended IDAMYCIN PFS Dosage in Patients with Renal Impairment In patients with renal impairment, reduce the dose of IDAMYCIN PFS as described in Table 1 [see Use in Specific Populations (8.6)]. Table 1: Recommended IDAMYCIN PFS Dosage for Patients with Renal Impairment Renal Impairment/Estimated GFR Dosage Modification GFR greater than or equal to 30 mL/min No adjustment needed GFR less than 30 mL/min Reduce the dose by 33% Hemodialysis Reduce the dose by 33%
2.4 Recommended
2.4 Recommended IDAMYCIN PFS Dosage in Patients with Hepatic Impairment In patients with hepatic impairment, reduce the dose of IDAMYCIN PFS as described in Table 2 [see Use in Specific Populations (8.7)]. Table 2: Recommended IDAMYCIN PFS Dosage for Patients with Hepatic Impairment Serum Bilirubin Dosage Less than or equal to 2.6 mg/dL No adjustment needed Greater than 2.6 mg/dL and less than 5 mg/dL Reduce the dose by 50% Greater than 5 mg/dL Avoid Use
2.5 Preparation
2.5 Preparation
- IDAMYCIN PFS is a hazardous drug. Follow applicable special handling and disposal procedures. 1
- Do not mix IDAMYCIN PFS or administer as an infusion with other drugs or heparin.
- Avoid prolonged contact with any solution of an alkaline pH, as this will result in degradation of IDAMYCIN PFS.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- Withdraw the volume of IDAMYCIN PFS needed based on the required dose.
- Do not further dilute prior to administration (see section
2.6 Administration
2.6 Administration).
- Discard unused portion.
2.6 Administration
2.6 Administration
- IDAMYCIN PFS is for intravenous infusion only.
- Prior to administration, flush the intravenous catheter used for IDAMYCIN PFS administration to ensure patency and to minimize the risk of extravasation.
- Administer IDAMYCIN PFS over 10 to 15 minutes into the tubing of a freely running intravenous infusion of 0.9% Sodium Chloride Injection or 5% Dextrose Injection.
- Closely monitor the infusion site for extravasation or drug infiltration during administration. Manage cases of extravasation as per institutional guidelines.
- Immediately discontinue the infusion if extravasation occurs [see Warnings and Precautions (5.3)].
Dosing: Altered kidney function
2.3 Recommended IDAMYCIN PFS Dosage in Patients with Renal Impairment In patients with renal impairment, reduce the dose of IDAMYCIN PFS as described in Table 1 [see Use in Specific Populations (8.6)]. Table 1: Recommended IDAMYCIN PFS Dosage for Patients with Renal Impairment Renal Impairment/Estimated GFR Dosage Modification GFR greater than or equal to 30 mL/min No adjustment needed GFR less than 30 mL/min Reduce the dose by 33% Hemodialysis Reduce the dose by 33%
8.6 Renal Impairment Reduce dosage of IDAMYCIN PFS in patients with GFR less than 30 mL/min and in patients on hemodialysis [see Dosage and Administration (2.3)]. Renal function should be evaluated prior to and during treatment with IDAMYCIN PFS. The effect of renal impairment on idarubicin hydrochloride or idarubicinol pharmacokinetics is unknown [see Clinical Pharmacology (12.3)].
However, renal impairment can affect the disposition of idarubicin hydrochloride based on a mechanistic understanding of idarubicin hydrochloride elimination. Treatment was not given if creatinine serum levels exceeded 2 mg/dL in multiple clinical trials.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Reduce dosage of IDAMYCIN PFS in patients with serum bilirubin levels greater than 2.6 mg/dL and less than 5 mg/dL [see Dosage and Administration (2.4)]. Do not administer IDAMYICN PFS in patients with serum bilirubin levels greater than 5 mg/dL. Liver function should be evaluated prior to and during treatment with IDAMYCIN PFS.
The effect of hepatic impairment on idarubicin hydrochloride or idarubicinol pharmacokinetics is unknown [see Clinical Pharmacology (12.3)]. However, hepatic impairment can affect the disposition of idarubicin hydrochloride based on a mechanistic understanding of idarubicin hydrochloride elimination.
2.4 Recommended IDAMYCIN PFS Dosage in Patients with Hepatic Impairment In patients with hepatic impairment, reduce the dose of IDAMYCIN PFS as described in Table 2 [see Use in Specific Populations (8.7)]. Table 2: Recommended IDAMYCIN PFS Dosage for Patients with Hepatic Impairment Serum Bilirubin Dosage Less than or equal to 2.6 mg/dL No adjustment needed Greater than 2.6 mg/dL and less than 5 mg/dL Reduce the dose by 50% Greater than 5 mg/dL Avoid Use
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of IDAMYCIN PFS in pediatric patients have not been established. Pediatric patients may be at greater risk for anthracycline-induced acute manifestations of cardiotoxicity or late cardiovascular dysfunction. The safety and effectiveness of idarubicin hydrochloride were assessed but not established in two open label clinical studies in pediatric patients aged 1 to <17 years with leukemia and solid tumors.
The pharmacokinetics of idarubicin hydrochloride in these pediatric patients were within range of that observed in adult patients given a similar dose based on body surface area. Idarubicin hydrochloride and idarubicinol were detected in CSF samples obtained in these patients; the clinical relevance of these findings is unknown.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Patients over 60 years of age who were undergoing induction therapy experienced congestive heart failure, serious arrhythmias, chest pain, myocardial infarction, and asymptomatic declines in LVEF more frequently than younger patients [see Adverse Reactions (6.1)].
Administration
2.5 Preparation • IDAMYCIN PFS is a hazardous drug. Follow applicable special handling and disposal procedures. 1 • Do not mix IDAMYCIN PFS or administer as an infusion with other drugs or heparin. • Avoid prolonged contact with any solution of an alkaline pH, as this will result in degradation of IDAMYCIN PFS. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. • Withdraw the volume of IDAMYCIN PFS needed based on the required dose. • Do not further dilute prior to administration (see section
2.6 Administration). • Discard unused portion.
2.6 Administration • IDAMYCIN PFS is for intravenous infusion only. • Prior to administration, flush the intravenous catheter used for IDAMYCIN PFS administration to ensure patency and to minimize the risk of extravasation. • Administer IDAMYCIN PFS over 10 to 15 minutes into the tubing of a freely running intravenous infusion of 0.9% Sodium Chloride Injection or 5% Dextrose Injection. • Closely monitor the infusion site for extravasation or drug infiltration during administration. Manage cases of extravasation as per institutional guidelines. • Immediately discontinue the infusion if extravasation occurs [see Warnings and Precautions (5.3) ] .
US FDA labelDosage forms
Philippines
- Concentrate solution for injection: 5 mg/5 mL
- Concentratesolution for injection: 5 mg/5 mL
- Lyophilized powder for injection: 5 mg
- Lyophilized powder for iv injection: 5 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Idarubicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Idacord 5Idarubicin Hydrochloride | 5mg/5mL Concentrate Solution For Injection (IV)6 mL-capacity USP Type I clear and colorless glass vial with gray rubber stopper and aluminum seal with orange plastic flip-off cap (box of 1’s) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited – Philippine Branch OfficeImporter: Accord Healthcare Limited-Philippine Branch Office | DRP-12449 | Aug 10, 2027 | |
IdaGet-5Idarubicin hydrochloride | 5 mg Lyophilized Powder for Injection (IV)5mL-Capacity Type I Amber Glass Vial Sealed with Bromobutyl Rubber Stopper and Red Aluminum Seal Flip-Off Cap x 1's (Box of 1's) | RxVAT-exempt | Biozenta Lifescience Pvt. Ltd.India | 2MG Incorporated | DRP-17549 | Jan 23, 2031 | |
IdaruGet-5Idarubicin hydrochloride | 5 mg / 5 mL ConcentrateSolution for Injection (I.V.)6 mL-capacity USP Type I clear and colorless glass vial with gray rubber stopper and aluminum seal with orange plastic flip-off cap (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Getmeds Philippines Inc.Importer: Accord Healthcare Limited - Philippine Branch Office | DRP-12449-01 | Aug 10, 2027 | |
ZavedosIdarubicin Hydrochloride | 5 mg Lyophilized Powder for IV Injection10 mL-Capacity Type I Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminum Seal with Polypropylene Flip-off Top (Box of 1's) | RxVAT-exempt | Corden Pharma Latina S.p.A.Italy | Pfizer, Inc. | DR-XY15884 | Jul 31, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 5 mg/5 mL (1 mg/mL), 10 mg/10 mL (1 mg/mL), and 20 mg/20 mL (1 mg/mL) of idarubicin hydrochloride as a clear, orange-red, preservative-free aqueous solution in a single-dose vial. Injection: 5 mg/5 mL (1 mg/mL), 10 mg/10 mL (1 mg/mL), and 20 mg/20 mL (1 mg/mL) solution in a single-dose vial. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Myelosuppression: Severe myelosuppression resulting in severe infection, septic shock, hemorrhage, or death may occur. Obtain complete blood counts prior to each treatment and closely monitor patients during treatment for possible clinical complications due to myelosuppression. (5.4)
- • Tumor Lysis Syndrome: During treatment, monitor blood chemistries and manage promptly. Treat as clinically indicated. (5.5)
- • Hypersensitivity: Monitor patients for hypersensitivity reactions and manage as clinically indicated. (5.6)
- • Renal Impairment: Assess renal function prior to and during treatment. Reduce the dose in patients on dialysis or those with GFR <30 mL/min. (2.3, 5.7, 8.6)
- • Hepatic Impairment: Obtain liver tests prior to and during therapy. Reduce dose in patients with serum bilirubin levels of 2.6 to 5 mg/dL. Avoid use in patients with serum bilirubin greater than 5 mg/dL. (2.4, 5.8, 8.7)
- • Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (5.9, 8.1, 8.3)
5.1 Cardiomyopathy
5.1 Cardiomyopathy IDAMYCIN PFS can cause myocardial damage, including left ventricular failure, or congestive heart failure (CHF). In pediatric patients, anthracycline-induced cardiomyopathy included impaired left ventricular systolic performance, reduced contractility, congestive heart failure, or death. Cardiomyopathy may develop during treatment with IDAMYCIN PFS or up to several years after completion of treatment.
Cases of pericarditis and myocarditis have also been reported at a lower incidence and may not be dose related. The risk of cardiomyopathy is generally proportional to the cumulative exposure to anthracycline drugs. Include prior doses of other anthracyclines or anthracenediones in calculations of total cumulative dosage for idarubicin hydrochloride.
In adult patients, at cumulative doses exceeding 90 mg/m 2 of idarubicin hydrochloride, there is an increased incidence of drug-induced congestive heart failure. The tolerable limit may be lower in patients who received radiation therapy to the mediastinum. Concomitant use of cardiotoxic drugs may increase the risk of idarubicin-induced cardiac toxicity or may result in cardiotoxicity at a lower cumulative anthracycline dose.
Calculate the lifetime cumulative anthracycline exposure prior to each cycle of IDAMYCIN PFS. IDAMYCIN PFS use is not recommended in patients whose lifetime anthracycline exposure has reached the maximum cumulative limit. Assess left ventricular cardiac function (e.g., MUGA or echocardiogram) prior to initiation of IDAMYCIN PFS.
Perform serial cardiac monitoring, which may include electrocardiograms and/or determination of systolic ejection fraction, in all patients during treatment to detect acute changes and after treatment to detect delayed cardiotoxicity. Increase the frequency of assessments as the cumulative anthracycline dose increases or in patients with risk factors for cardiac toxicity.
Consider long-term periodic evaluation of cardiac function in these patients. Adults 65 years of age and older, or with pre-existing cardiac disease, may have an increased risk of anthracycline-induced cardiac toxicity, or may experience cardiotoxicity at a lower cumulative anthracycline dose. Discontinue IDAMYCIN PFS in patients who develop signs or symptoms of cardiomyopathy.
5.2 Secondary Malignancies
5.2 Secondary Malignancies The risk of developing secondary AML and myelodysplastic syndrome (MDS) is increased following treatment with IDAMYCIN PFS. AML and MDS have occurred in patients treated with anthracycline topoisomerase inhibitors when used in combination with other antineoplastic agents or radiation therapy. Monitor patients long-term for the development of secondary malignancies.
5.3 Severe Local Tissue Necrosis with Extravasation
5.3 Severe Local Tissue Necrosis with Extravasation Extravasation of IDAMYCIN PFS at the site of intravenous administration can cause severe local tissue injury including blistering, ulceration, thrombophlebitis, and necrosis requiring wide excision of the affected area and skin grafting. Monitor patients during the IDAMYCIN PFS infusion for signs and symptoms of extravasation (including erythematous streaking, burning, or stinging sensations, thrombosis) or perivenous infiltration.
If extravasation occurs during administration, immediately discontinue the intravenous injection or continuous intravenous infusion of IDAMYCIN PFS and manage per institutional guidelines [see Dosage and Administrations (2.6)].
5.4 Severe Myelosuppression
5.4 Severe Myelosuppression Severe myelosuppression resulting in severe infection, septic shock, hemorrhage, or death may occur during treatment with IDAMYCIN PFS, and some patients may require blood product transfusions. Obtain complete blood counts prior to each treatment and closely monitor patients during treatment for possible clinical complications due to myelosuppression.
Delay next dose of IDAMYCIN PFS if severe myelosuppression has not improved. Consider dose reduction for patients with prolonged myelosuppression [see Dosage and Administrations (2.2)]. Discontinue IDAMYCIN PFS in patients who develop severe myelosuppression.
5.5 Tumor Lysis Syndrome
5.5 Tumor Lysis Syndrome IDAMYCIN PFS may induce tumor lysis syndrome. Patients at risk of tumor lysis syndrome are those with rapidly growing tumors or high tumor burden prior to treatment. During and after initial treatment, monitor blood chemistries and manage abnormalities promptly. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent hyperuricemia may minimize potential complications of tumor lysis syndrome.
5.6 Hypersensitivity
5.6 Hypersensitivity IDAMYCIN PFS can cause hypersensitivity reactions. Clinical signs and symptoms of hypersensitivity may include, but are not limited to, rash and urticaria [see Adverse Reactions (6.1)]. Monitor patients for signs and symptoms of hypersensitivity during treatment with IDAMYCIN PFS and manage as clinically indicated.
5.7 Use in Patients with Renal Impairment
5.7 Use in Patients with Renal Impairment Renal impairment may result in increased risk of toxicity in patients treated with IDAMYCIN PFS [see Use in Specific Populations (8.6)]. Assess renal function prior to and during treatment with IDAMYCIN PFS. Reduce the dose of IDAMYCIN PFS in patients on dialysis or those with GFR <30 mL/min [see Dosage and Administration (2.3)].
5.8 Use in Patients with Hepatic Impairment
5.8 Use in Patients with Hepatic Impairment Hepatic impairment may result in increased risk of toxicity in patients treated with IDAMYCIN PFS [see Use in Specific Populations (8.7)]. Obtain liver tests including ALT, AST, alkaline phosphatase, and bilirubin prior to and during therapy. Reduce the dose of IDAMYCIN PFS in patients with serum bilirubin levels of 2.6 to 5 mg/dL.
Avoid use of IDAMYCIN PFS in patients with serum bilirubin greater than 5 mg/dL [see Dosage and Administration (2.4)].
5.9 Embryo-Fetal Toxicity
5.9 Embryo-Fetal Toxicity Based on findings from animal reproductive studies and its mechanism of action [see Clinical Pharmacology (12.1)], IDAMYCIN PFS can cause fetal harm when administered to pregnant women. Idarubicin hydrochloride was embryotoxic and teratogenic in rats at doses of 1.2 mg/m 2 /day or 0.1 times the human dose, which was not maternally toxic.
Idarubicin hydrochloride was embryotoxic but not teratogenic in rabbits at doses of 2.4 mg/m 2 /day or 0.2 times the human dose, which was maternally toxic. Advise women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with IDAMYCIN PFS and for 6.5 months after the last dose.
Advise males with female partners of reproductive potential to use effective contraception for 3.5 months after the last dose [see Use in Specific Populations (8.1, 8.3) and Nonclinical Toxicology (13.1)].
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:
- Cardiomyopathy [see Warnings and Precautions (5.1)]
- Secondary Malignancies [see Warnings and Precautions (5.2)]
- Severe Local Tissue Necrosis with Extravasation [see Warnings and Precautions (5.3)]
- Severe Myelosuppression [see Warnings and Precautions (5.4)]
- Tumor Lysis Syndrome [see Warnings and Precautions (5.5)]
- Hypersensitivity [see Warnings and Precautions (5.6)] Most common adverse reactions (≥30%) are infection, nausea/vomiting, alopecia, abdominal pain/diarrhea, hemorrhage, mucositis, dermatologic, mental status changes, and pulmonary disorders. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials and Postmarketing Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of IDAMYCIN PFS in combination with cytarabine has been evaluated in four controlled clinical studies with 823 patients with AML randomized to receive idarubicin hydrochloride (n=401) or daunorubicin (n=422) [see Clinical Studies (14)]. Southeastern Cancer Study Group (SEG) Table 3 below lists the adverse reactions that occurred in patients with AML who received idarubicin hydrochloride in the Southeastern Cancer Study Group (SEG) study. Table 3: Adverse Reactions (≥5%) in Patients with AML Who Received Idarubicin Hydrochloride as Induction Therapy in the SEG Trial Adverse Reactions Idarubicin with Cytarabine (N=110) Daunorubicin with Cytarabine (N=118) All Grades % All Grades % Infection 95 97 Nausea/Vomiting 82 80 Alopecia 77 72 Abdominal Pain/Diarrhea 73 68 Hemorrhage 63 65 Mucositis 50 55 Dermatologic 46 40 Mental Status Changes 41 34 Pulmonary Disorders 39 39 Fever 26 28 Headache 20 24 Cardiac Disorder 16 24 Peripheral Neuropathy 7 9 Clinically relevant adverse reactions in <5% of patients who received idarubicin hydrochloride included pulmonary allergy, seizure, and cerebellar adverse reactions. Other Clinical Trials The following additional adverse reactions associated with the use of idarubicin hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac
- Asymptomatic declines in Left Ventricular Ejection Fraction (LVEF)
- Chest pain
- Congestive heart failure
- Myocardial infarction
- Serious arrhythmias including atrial fibrillation Dermatologic
- Bullous erythrodermatous rash (palms and soles)
- Generalized rash
- Radiation recall (skin reaction)
- Urticaria Gastrointestinal
- Severe enterocolitis with perforation Hepatic
- Increased ALT/AST Renal
- Renal impairment
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reactions | Idarubicin with Cytarabine(N=110) | Daunorubicin with Cytarabine(N=118) |
| All Grades% | All Grades% | |
| Infection | 95 | 97 |
| Nausea/Vomiting | 82 | 80 |
| Alopecia | 77 | 72 |
| Abdominal Pain/Diarrhea | 73 | 68 |
| Hemorrhage | 63 | 65 |
| Mucositis | 50 | 55 |
| Dermatologic | 46 | 40 |
| Mental Status Changes | 41 | 34 |
| Pulmonary Disorders | 39 | 39 |
| Fever | 26 | 28 |
| Headache | 20 | 24 |
| Cardiac Disorder | 16 | 24 |
| Peripheral Neuropathy | 7 | 9 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from animal reproduction studies and its mechanism of action, IDAMYCIN PFS can cause fetal harm when administered to a pregnant woman [see Warnings and Precautions (5.9)]. There are no available data on the use of IDAMYCIN PFS in pregnant women to evaluate for a drug-associated risk.
Idarubicin hydrochloride was embryotoxic and teratogenic in rats at doses of 1.2 mg/m 2 /day or 0.1 times the human dose. Idarubicin hydrochloride was embryotoxic but not teratogenic in rabbits at doses of 2.4 mg/m 2 /day or 0.2 times the human dose [see Data]. Advise women of the potential risk to the fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data Idarubicin hydrochloride was embryotoxic and teratogenic in the rat at a dose of 1.2 mg/m 2 /day or 0.1 times the human dose, which was not maternally toxic. Idarubicin hydrochloride was embryotoxic but not teratogenic in the rabbit even at a dose of 2.4 mg/m 2 /day or 0.2 times the human dose, which was maternally toxic.
Mechanism of action
12.1 Mechanism of Action Idarubicin hydrochloride has antimitotic and cytotoxic activity through forming complexes with the DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Idarubicin hydrochloride exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.
Pharmacokinetics
Elimination Idarubicin hydrochloride mean (range) terminal half-life is 22 (4 to 48) hours when used as a single agent and 20 (7 to 38) hours when used in combination with cytarabine.
Idarubicinol mean terminal half-life exceeds 45 hours; hence, its plasma levels are sustained for a period greater than 8 days.
Excretion Idarubicin hydrochloride is eliminated predominately by biliary excretion and to a lesser extent by renal excretion, primarily as idarubicinol.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Idarubicin hydrochloride pharmacokinetics were determined in adult leukemia patients with normal renal and hepatic function following intravenous administration of idarubicin hydrochloride 10 to 12 mg/m 2 daily for 3 to 4 days as a single agent or combined with cytarabine. Accumulation is predicted to be 1.7-fold for idarubicin hydrochloride and 2.3-fold for idarubicinol following multiple idarubicin hydrochloride dosing.
Distribution Idarubicin hydrochloride exhibits a rapid distributive phase with a very large volume of distribution. Idarubicin hydrochloride is approximately 97% and idarubicinol is 94% bound to plasma proteins and the binding is concentration independent. Concentrations of idarubicin hydrochloride and idarubicinol in nucleated blood and bone marrow cells are more than a hundred times the plasma concentrations.
Elimination Idarubicin hydrochloride mean (range) terminal half-life is 22 (4 to 48) hours when used as a single agent and 20 (7 to 38) hours when used in combination with cytarabine. Idarubicin hydrochloride plasma clearance is twice the expected hepatic plasma flow. Idarubicinol mean terminal half-life exceeds 45 hours; hence, its plasma levels are sustained for a period greater than 8 days.
Metabolism The idarubicin hydrochloride is primary metabolized to the active metabolite idarubicinol which has cytotoxic activity that likely contributes to the effects of idarubicin hydrochloride. Excretion Idarubicin hydrochloride is eliminated predominately by biliary excretion and to a lesser extent by renal excretion, primarily as idarubicinol.
Specific Populations The effect of renal or hepatic impairment on idarubicin hydrochloride or idarubicinol pharmacokinetics is unknown.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Idarubicin (as hydrochloride) |
| PNF listing | Inj.: powder, 5 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Idamycin PFS · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 27, April 15, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a5a6d93-cc1e-4d7f-8da1-446c134503b3
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .